1415573-10-2

Upstream product

• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 
• 66405-41-2 (4-oxo-cyclohexyl)-acetic acid methyl ester 
• 78002-68-3 (hydroxy-4 cyclohexyl)acetate de methyle-cis 
• 1415573-09-9 methyl 2-(4-(piperidin-4-yloxy)cyclohexyl)acetate 
• 1415573-08-8 methyl [4-(pyridin-4-yloxy)cyclohexyl]acetate 
• 99183-13-8 methyl 2-(4-hydroxycyclohexyl)acetate 
• 626-64-2 pyridin-4-ol 

Downstream Products

• 1415573-13-5 cis methyl 2-(4-(piperidin-4-yloxy)cyclohexyl)acetate 
• 1415573-14-6 [cis-4-(piperidin-4-yloxy)cyclohexyl]acetic acid 

Relevant academic research and scientific papers

A biocatalytic/reductive etherification approach to substituted piperidinyl ethers

A synthetically useful protocol has been developed for the preparation of highly functionalized piperidinyl ethers. Biocatalytic reduction of cyclhexanones 7, 10, and 14 allows for the preparation of both cis- and trans diastereomers with an extremely high degree of stereochemical control. Reductive etherification of the corresponding trimethylsilylethers with 1-(benzyloxycarbonyl)-4-piperidinone 17 in the presence of triethylsilane and catalytic TMSO-Tf provides the desired piperidinyl ethers in good to excellent yields. Finally hygrogenolysis of the nitrogen protecting group leads to piperidinyl ethers in near quantitative yields. Application of the methodology to a range of piperidinyl ethers, including the core scaffolds of diphenylpyraline and ebastine, is also described.

IMIDAZOLE DERIVATIVES

Described herein are compounds of formula (I), The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.